Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 8.9% – What’s Next?

Posted by Chris Copeland on May 30th, 2026

Shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) were up 8.9% on Thursday . The stock traded as high as $3.09 and last traded at $3.06. Approximately 33,033 shares changed hands during mid-day trading, an increase of 152% from the average daily volume of 13,127 shares. The stock had previously closed at $2.81.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on TCRT

Alaunos Therapeutics Trading Down 6.9%

The firm has a market cap of $69.60 million, a price-to-earnings ratio of -1.34 and a beta of -1.13. The stock has a fifty day moving average price of $2.77 and a 200 day moving average price of $3.04.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.59) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP bought a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is currently owned by institutional investors and hedge funds.

Alaunos Therapeutics Company Profile

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.